New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
10:04 EDTPERI, GXP, STZ, ABBV, NVEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with a Buy at Jefferies... AbbVie (ABBV) initiated with an Outperform at Wells Fargo... Great Plains Energy (GXP) initiated with a Buy at SunTrust... NV Energy (NVE) initiated with a Neutral at SunTrust... Perion Network (PERI) initiated with a Buy at Benchmark Co... Constellation Brands (STZ) initiated with a Buy at Buckingham.
News For ABBV;GXP;NVE;STZ;PERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
15:44 EDTGXPKCP&L plans to install, operate 1,000 electric vehicle charging stations
Subscribe for More Information
January 20, 2015
17:17 EDTGXPGreat Plains Energy unit announces plans to stop burning coal at three plants
Kansas City Power & Light Company, or KCP&L, a subsidiary of Great Plains Energy, announced that in the coming years it will no longer burn coal at three of its coal-fired power plants, Montrose Station, one of its units at Lake Road Station and two of its units at Sibley Station. This announcement furthers the companys commitment to a sustainable energy future and balanced generation portfolio. Lake Roads boiler already has the ability to burn natural gas and the company plans to operate on natural gas once it ceases coal combustion. In the coming years, KCP&L will make final decisions regarding whether to retire the units at Montrose and Sibley, or convert them to an alternative fuel source. The decision comes in part as a result from recent Environmental Protection Agency regulations, which would require KCP&L to make significant environmental upgrades in the coming years in order to continue burning coal at these power plants. While this decision will impact employees at Montrose, Lake Road and Sibley, the utility does not anticipate that any employees will lose jobs as a result. KCP&L will find job opportunities within the company for displaced employees.
January 16, 2015
10:10 EDTABBVAbbVie announces FDA approval of DUOPA enteral suspension
Subscribe for More Information
07:04 EDTABBVEnanta says EU grants marketing authorizations for AbbVie's Viekirax
Subscribe for More Information
05:05 EDTABBVAbbVie granted marketing authorization by EC for VIEKIRAX + EXVIERA
AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX + EXVIERA. The treatment has been approved with or without ribavirin for patients with genotype 1 chronic hepatitis C virus infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 chronic hepatitis C patients.
January 15, 2015
11:20 EDTABBVGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:37 EDTSTZKraft rises after Goldman gets less cautious on food space, ups stock to buy
Shares of Kraft Foods (KRFT) are climbing after Goldman Sachs upgraded the stock to Buy and placed the shares on its Conviction List. WHAT'S NEW: Costs for food makers are declining as commodity prices drop, Goldman Sachs analyst Judy Hong wrote in a note to investors today. Kraft is among the U.S. food companies that benefits the most from lower costs, the analyst stated. Additionally, Kraft's pricing power is one of the strongest in the group and it is heavily exposed to the U.S. economy, the analyst stated. WHAT'S NOTABLE: Hong's upgrade of Kraft was part of a note in which she took a more balanced view of the U.S. consumer staples sector. The analyst upgraded the Food sector to Neutral from Cautious, noting that consumer staples stocks with outsized exposure to the U.S. market should be boosted by strong U.S. growth and more favorable foreign exchange dynamics than their peers. In addition to Kraft, the analyst identified the following stocks as her top picks within the consumer staples sector: Monster Beverage (MNST), Constellation Brands (STZ), Coca-Cola Enterprises (CCE), Keurig Green Mountain (GMCR), Freshpet (FRPT), Mead Johnson (MJN), and Estee Lauder (EL). Goldman also upgraded Hershey (HSY), Dr. Pepper Snapple (DPS), and Clorox (CLX), all to Neutral from Sell, downgraded cigarette maker Philip Morris (PM) to Sell from Neutral and downgraded brewer Molson Coors (TAP) to Neutral from Buy. PRICE ACTION: In early trading, Kraft climbed 3.7% to $65 per share.
07:37 EDTSTZConstellation Brands initiated with a Buy at Argus
Subscribe for More Information
January 14, 2015
17:02 EDTSTZConstellation Brands names Bill Newlands Chief Growth Officer
Subscribe for More Information
12:25 EDTABBVAbbVie says pipeline is 'most robust it's ever been'
12:09 EDTABBVAbbVie says 'strongly' committed to dividend, returning cash to shareholders
Subscribe for More Information
12:00 EDTABBVAbbVie says guidance to be further refined as HCV launch progresses
11:59 EDTABBVAbbVie repeats FY15 adjusted EPS view $4.25-$4.45, consensus $4.30
Subscribe for More Information
January 13, 2015
12:15 EDTABBVExpress Scripts CEO says Gilead relationship 'important' going forward
Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
11:48 EDTSTZConstellation Brands upgraded to Hold from Sell at Societe Generale
Subscribe for More Information
10:00 EDTGXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:31 EDTGXPGreat Plains Energy upgraded to Buy from Neutral at Goldman
Subscribe for More Information
January 12, 2015
08:01 EDTABBVAbbVie announces FDA approval of DUOPA enteral suspension
The FDA has approved AbbVie's DUOPA enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. DUOPA is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube. DUOPA was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the U.S.
07:17 EDTABBVJPMorgan to hold a conference
Subscribe for More Information
06:36 EDTPERIPerion Network names Miki Kolko CTO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use